# CME Group Inc. (CME) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Financial Services / Capital Markets. Price $304.06, market value $108.8 billion.

## Valuation
- **P/E (trailing): 24.9×** (5-yr avg 22.8×, 3-yr avg 22.8×). CME Group Inc. trades at 24.9× trailing earnings, close to its own five-year average of 22.8×. The Financial Services median in the September 2026 study was 13.1×. Forward P/E is 23.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.49**. A PEG of 1.49 is in the range usually read as fairly priced for its growth.
- **Price / sales: 15.6×**. Each dollar of revenue is priced at 15.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 4.0%** (5-yr avg 4.6%). Free cash flow equals 4.0% of the market value, in line with its five-year average of 4.6%.
- **Earnings yield: 4.0%**. The inverse of the P/E: 4.0% of the price is earned each year.

## Profitability
- **Operating margin: 65.7%**. 65.7% of revenue is left after running the business, an exceptional level.
- **Net margin: 62.5%**. 62.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.2%**. 14.2% on shareholders' equity is solid.
- **Return on invested capital: 14.9%**. Return on all capital, debt included, is 14.9%.
- **Return on assets: 2.2%**. Each dollar of assets produces 2.2% of profit; low single digits are normal for banks and insurers.

## Growth
- **Revenue growth (1 yr): 6.4%** (3-yr 9.1%/yr, 5-yr 6.0%/yr). Revenue grew 6.4% over the last year, against 6.0% a year compounded over five years.
- **EPS growth (1 yr): 15.4%** (3-yr 14.7%/yr, 5-yr 13.7%/yr). Earnings per share rose 15.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 12.2%/yr**. Free cash flow has compounded at 12.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.
- **Cash and short-term investments: $4.4 billion**. Leverage ratios are shown differently for banks and insurers, whose balance sheets are built on deposits and reserves; use return on equity and the regulatory capital in the filings instead.

## Dividends
- **Dividend yield: 1.71%** ($5.15 per share, trailing). CME Group Inc. yields 1.71%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 97%** (94% of free cash flow). 97% of earnings goes out as dividends, leaving a thin cushion.
- **Dividend growth (5 yr): -3.3%/yr** (1-yr -51.9%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover CME Group Inc.; the consensus is buy, with an average price target of $317.06 (+4% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 19.3%** (YTD 15.4%, 3-mo 15.1%). The shares are up 19.3% over twelve months including dividends.
- **From 52-week high: -7.6%** (39.3% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): -0.36** (volatility 25%). Beta of -0.36 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CME · Page: https://foliofundamentals.com/stocks/cme

Not investment advice.